Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: Case report and review of the literature

Dermatology

Volumn 230, Issue 3, 2015, Pages 204-207

  Català, Alba ^a   Roé, Esther ^a   Dalmau, Joan ^a   Pomar, Virginia ^a   Muñoz, Carme ^a   Yelamos, Oriol ^a   Puig, Luis ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adalimumab; Anti tumour necrosis factor; Cutaneous leishmaniasis; Leishmaniasis; Liposomal amphotericin; Pentavalent antimonials; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B LIPID COMPLEX; HEMOGLOBIN; METHOTREXATE; PROTOZOON ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AMASTIGOTE; ANEMIA; ARTICLE; CASE REPORT; DISEASE DURATION; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEISHMANIA; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN EXAMINATION; SKIN LEISHMANIASIS; TREATMENT DURATION; VISCERAL LEISHMANIASIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925175276     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000370238     Document Type: Article

References (47)

1. Grimaldi G Jr, Tesh RB: Leishmaniases of the New World: Current concepts and implications for future research. Clin Microbiol Rev 1993; 6: 230-250.
2. Ready PD: Leishmaniasis emergence in Europe. Euro Surveill 2010; 15: 19505.
3. Titus RG, Sherry B, Cerami A: Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989; 170: 2097-2104.
4. Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW: Role and effect of TNF-Alpha in experimental visceral leishmaniasis. J Immunol 1994; 153: 768-775.
5. Martin-Mola E, Balsa A: Infectious complications of biologic agents. Rheum Dis Clin North Am 2009; 35: 183-199.
6. Moral L, Rubio EM, Moya M: A leishmanin skin test survey in the human population of l'Alacanti region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 2002; 96: 129-132.
7. Berman JD: Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
8. Sundar S: Diagnosis of kala-Azar-An important stride. J Assoc Physicians India 2003; 51: 753-755.
9. World Health Organization: Control of the Leishmaniases. Technical Report Series No. 793. Geneva, World Health Organization, 1990.
10. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M: Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am J Trop Med Hyg 2008; 79: 839-842.
11. Jewell AP, Giles FJ: Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia. Leuk Lymphoma 1996; 21: 347-349.
12. Czechowicz RT, Millard TP, Smith HR, Ashton RE, Lucas SB, Hay RJ: Reactivation of cutaneous leishmaniasis after surgery. Br J Dermatol 1999; 141: 1113-1116.
13. Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S: Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis 2014; 58: 1424-1429.
14. Liew FY, Parkinson C, Millott S, Severn A, Carrier M: Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 1990; 69: 570-573.
15. Baixauli Rubio A, Rodriguez Gorriz E, Campos Fernandez C, Calvo Catala J, Garcia Vicente S: Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis. An Med Interna 2003; 20: 276-277.
16. Romani-Costa V, Sanchez C, Moya F, Estany C: Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin 2004; 22: 310.
17. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgesen C, Sany J: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005; 23: 891-892.
18. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 2006; 45: 1446-1448.
19. Kone-Paut I, Retornaz K, Garnier JM, Bader-Meunier B: Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (anakinra). Clin Exp Rheumatol 2007; 25: 119.
20. Bagalas V, Kioumis I, Argyropoulou P, Patakas D: Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007; 26: 1344-1345.
21. Tektonidou MG, Skopouli FN: Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008; 27: 541-542.
22. Franklin G, Greenspan J, Chen S: Anti-Tumor necrosis factor-Alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis. Ann Clin Lab Sci 2009; 39: 192-195.
23. Balta-Cruz S, Alsina-Gibert M, Mozos-Rocafort A, Cervera C, Colomo-Saperas L, Del Rio A, Estrach-Panella T: Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis. Acta Derm Venereol 2009; 89: 432-433.
24. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, Salvador G, Garau J: Risk factors for opportunistic infections in infliximabtreated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-337.
25. De Leonardis F, Govoni M, Lo Monaco A, Trotta F: Visceral leishmaniasis and anti-TNF-Alpha therapy: case report and review of the literature. Clin Exp Rheumatol 2009; 27: 503-506.
26. Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV: Leishmaniasis, autoimmune rheumatic disease, and anti-Tumor necrosis factor therapy, Europe. Emerg Infect Dis 2009; 15: 956-959.
27. Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Loscher T: Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009; 81: 52-54.
28. Schneider P, Bouaziz JD, Foulet F, Duong TA, Allanore LV, Bagot M: Multifocal cutaneous leishmaniasis due to Leishmania infantum under adalimumab therapy. Ann Dermatol Venereol 2009; 136: 815-816.
29. Jeziorski E, Blanchet C, Ludwig C, Lalande M, Coste V, Dereure J, Rodiere M: Pseudotumoral-like recurrence of visceral leishmaniasis in a seven-year-old girl. Arch Pediatr 2009; 16(suppl 2):S129-S131.
30. Hakimi S, Riviere S, Del Giudice P, Dereure J, Le Quellec A: Localized cutaneous leishmaniasis due to Leishmania infantum in a patient treated with infliximab. Dermatology 2010; 220: 63-65.
31. Kritikos K, Haritatos E, Tsigkos S, Gounari P, Skrapari I, Gounaris T, Sioula E: An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol 2010; 16: 38-39.
32. Moreno D, Martinez P, Berbegal J, Femenia M: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review. Enferm Infecc Microbiol Clin 2010; 28: 261-262.
33. Molto A, Mateo L, Lloveras N, Olive A, Minguez S: Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 2010; 77: 271-273.
34. Erre GL, Mesina P, Tonelli N, Passiu G: Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol 2010; 28: 590-591.
35. Khan A, Coakley G, Cosgrove C, Lockwood D: Let off the leash: kala-Azar following the use of tumour necrosis factor antibodies. BMJ Case Rep 2010; 13: 2010.
36. Zanger P, Kotter I, Raible A, Gelanew T, Schonian G, Kremsner PG: Case report: Successful treatment of cutaneous leishmaniasis caused by Leishmania aethiopica with liposomal amphothericin B in an immunocompromised traveler returning from Eritrea. Am J Trop Med Hyg 2011; 84: 692-694.
37. Garcia-Castro JM, Javier-Martinez R, Caliz-Caliz R, Garcia-Sanchez A: Persistent inflammation of the nasal dorsum in a patient with rheumatoid arthritis treated with infliximab. Enferm Infecc Microbiol Clin 2012; 30: 40-42.
38. Gomes KW, Benevides AN, Vieira FJ, Burlamaqui MP, Vieira Mde A, Fontenelle LM: Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab. Rev Bras Reumatol 2012; 52: 447-452.
39. Besada E, Njalla RJ, Nossent JC: Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis. Rheumatol Int 2013; 33: 2687-2689.
40. Garcia-Gonzalez E, Guidelli GM, Bardelli M, Maggio R: Mucocutaneous leishmaniasis in a patient treated with anti-TNF-α therapy. Rheumatology (Oxford) 2012; 51: 1517-1518.
41. Romero-Mate A, Martinez-Sanchez D, Tardio JC, Moreno-Torres A, Garcia-Donoso C, Aguado-Lobo M, Espinosa-Lara P, Borbujo J: Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab. Dermatol Online J 2012; 18: 7.
42. Bousquet E, Mura F, Villain M, Riviere S, Konate A, Schneider C: Infectious complications in patients treated with anti-TNF-Alpha: two cases of leishmaniasis. J Fr Ophtalmol 2012; 35: 695-699.
43. Berry CE, Tsai J, Tierney A, Pickles R: Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. Med J Aust 2013; 198: 331-333.
44. Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, Henrique da Mota LM, de Menezes I, Aaron Scheinberg M: Leishmaniasis during anti-Tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum 2013; 43: 152-157.
45. Catala A, Barnadas MA, Munoz C, Puig L: Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: treatment with cryotherapy and intralesional meglumine antimonate. Actas Dermosifiliogr 2014; 105: 714-716.
46. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426.
47. Allenbach C, Launois P, Mueller C, Tacchini-Cottier F: An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection. Eur J Immunol 2008; 38: 720-731.